journal article·2020-10

Overcoming negatively charged tissue barriers: Drug delivery using cationic peptides and proteins

Armin Vedadghavami, Chenzhen Zhang, Ambika G. Bajpayee

Nano Today· Volume 34
Publisher page

Abstract

Negatively charged tissues are ubiquitous in the human body and are associated with a number of common diseases yet remain an outstanding challenge for targeted drug delivery. While the anionic proteoglycans are critical for tissue structure and function, they make tissue matrix dense, conferring a high negative fixed charge density (FCD) that makes drug penetration through the tissue deep zones and drug delivery to resident cells extremely challenging. The high negative FCD of these tissues is now being utilized by taking advantage of electrostatic interactions to create positively charged multi-stage delivery methods that can sequentially penetrate through the full thickness of tissues, create a drug depot and target cells. After decades of work on attempting delivery using strong binding interactions, significant advances have recently been made using weak and reversible electrostatic interactions, a characteristic now considered essential to drug penetration and retention in negatively charged tissues. Here we discuss these advances using examples of negatively charged tissues (cartilage, meniscus, tendons and ligaments, nucleus pulposus, vitreous of eye, mucin, skin), and delve into how each of their structures, tissue matrix compositions and high negative FCDs create barriers to drug entry and explore how charge interactions are being used to overcome these barriers. We review work on tissue targeting cationic peptide and protein-based drug delivery, compare and contrast drug delivery designs, and also present examples of technologies that are entering clinical trials. We also present strategies on further enhancing drug retention within diseased tissues of lower FCD by using synergistic effects of short-range binding interactions like hydrophobic and H-bonds that stabilize long-range charge interactions. As electrostatic interactions are incorporated into design of drug delivery materials and used as a strategy to create properties that are reversible, tunable and dynamic, bio-electroceuticals are becoming an exciting new direction of research and clinical work.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced Drug Delivery Systems · RNA Interference and Gene Delivery · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Epidemiology of osteoarthritis10.1016/j.cger.2010.03.001 ↗
2. Epidemiology of gout10.1016/j.rdc.2014.01.001 ↗
3. The rising prevalence of chronic low back pain10.1001/archinternmed.2008.543 ↗
4. Epidemiology and risk factors for IBD10.1038/nrgastro.2015.34 ↗
5. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
6. Progress in intra-articular therapy10.1038/nrrheum.2013.159 ↗
7. Intra-articular dexamethasone to inhibit the development of post-traumatic osteoarthritis10.1002/jor.23295 ↗
8. The knee meniscus: structure-function, pathophysiology, current repair techniques, and prospects for regeneration10.1016/j.biomaterials.2011.06.037 ↗
9. IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1β-mediated degradation of nucleus pulposus in vitro10.1186/ar3932 ↗
10. Pharmacokinetic aspects of retinal drug delivery10.1016/j.preteyeres.2016.12.001 ↗
11. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers10.1016/j.addr.2011.12.009 ↗
12. Transdermal drug delivery: progress and challenges10.1016/S1773-2247(14)50041-X ↗
13. Cartilage-targeting drug delivery: can electrostatic interactions help?10.1038/nrrheum.2016.210 ↗
14. Cartilage penetrating cationic peptide carriers for applications in drug delivery to avascular negatively charged tissues10.1016/j.actbio.2018.12.004 ↗
15. Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis10.1016/j.biomaterials.2013.09.091 ↗
16. Sustained intra-cartilage delivery of low dose dexamethasone using a cationic carrier for treatment of post traumatic osteoarthritis10.22203/eCM.v034a21 ↗
17. US10226427B2 - Surface binding of nanoparticle based drug delivery to tissue - Google Patents, (n.d.). https://patents.google.com/patent/US10226427B2/en (Accessed 25 November 2019).
18. US9289506B2 - Surface binding of nanoparticle based drug delivery to tissue - Google Patents, (n.d.). https://patents.google.com/patent/US9289506B2/en (accessed 25 November 2019).
19. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage10.1038/nmat2116 ↗
20. Cartilage-targeting dexamethasone prodrugs increase the efficacy of dexamethasone10.1016/j.jconrel.2018.12.025 ↗
21. Mucus adhesion- and penetration-enhanced liposomes for paclitaxel oral delivery10.1016/j.ijpharm.2017.12.044 ↗
22. Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage10.1021/acs.molpharmaceut.6b00445 ↗
23. Protein nanoparticles as drug delivery carriers for cancer therapy10.1155/2014/180549 ↗
24. Cell-penetrating peptides: possible transduction mechanisms and therapeutic applications (review)10.3892/br.2016.639 ↗
25. Cell penetrating peptides: a concise review with emphasis on biomedical applications10.1016/j.biopha.2018.09.097 ↗
26. Cell-penetrating peptides: from basic research to clinics10.1016/j.tips.2017.01.003 ↗
27. Polymeric nanoparticles in gene therapy: New avenues of design and optimization for delivery applications10.3390/polym11040745 ↗
28. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles10.2147/IJN.S36111 ↗
29. Cell-penetrating peptides for drug delivery across membrane barriers10.1517/17425247.5.1.105 ↗
30. Characterisation of cell-penetrating peptide-mediated peptide delivery10.1038/sj.bjp.0706279 ↗
31. Dual action of the PN159/KLAL/MAP peptide: increase of drug penetration across caco-2 intestinal barrier model by modulation of tight junctions and plasma membrane permeability10.3390/pharmaceutics11020073 ↗
32. Cell penetrating peptides: a concise review with emphasis on biomedical applications10.1016/j.biopha.2018.09.097 ↗
33. How charge distribution influences the function of membrane-active peptides: lytic or cell-penetrating?10.1016/j.biocel.2016.12.011 ↗
34. Toxicity of cationic lipids and cationic polymers in gene delivery10.1016/j.jconrel.2006.04.014 ↗
35. Cartilage-penetrating nanocarriers improve delivery and efficacy of growth factor treatment of osteoarthritis10.1126/scitranslmed.aat8800 ↗
36. Vectors based on reducible polycations facilitate intracellular release of nucleic acids10.1002/jgm.331 ↗
37. Cell-penetrating and cell-targeting peptides in drug delivery10.1016/j.bbcan.2008.03.001 ↗
38. Multistage nanoparticle delivery system for deep penetration into tumor tissue10.1073/pnas.1018382108 ↗
39. Current multistage drug delivery systems based on the tumor microenvironment10.7150/thno.16684 ↗
40. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency10.1016/j.bbrc.2005.07.142 ↗
41. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation10.1038/81359 ↗
42. Subconjunctival injection of XG-102, a c-jun N-terminal kinase inhibitor peptide, in the treatment of endotoxin-induced uveitis in rats10.1089/jop.2014.0019 ↗
43. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity10.1021/bc070077d ↗
44. Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides10.1016/j.apsb.2016.04.001 ↗
45. Spatial configuration and composition of charge modulates transport into a mucin hydrogel barrier10.1016/j.bpj.2013.07.050 ↗
46. Diffusion regulation in the vitreous humor10.1016/j.bpj.2015.10.002 ↗
47. Articular cartilage: structure, injuries and review of management10.1093/bmb/ldn025 ↗
48. Biochemistry of articular cartilage in health and disease10.1016/0009-9120(92)90224-G ↗
49. A detailed quantitative outcome measure of glycosaminoglycans in human articular cartilage for cell therapy and tissue engineering strategies10.1016/j.joca.2015.07.011 ↗
50. Knee osteoarthritis: pathophysiology and current treatment modalities10.2147/JPR.S154002 ↗
51. Osteoarthritis: toward a comprehensive understanding of pathological mechanism10.1038/boneres.2016.44 ↗
52. Green fluorescent proteins engineered for cartilage-targeted drug delivery: insights for transport into highly charged avascular tissues10.1016/j.biomaterials.2018.08.050 ↗
53. A rabbit model demonstrates the influence of cartilage thickness on intra-articular drug delivery and retention within cartilage10.1002/jor.22841 ↗
54. Charge based intra-cartilage delivery of single dose dexamethasone using Avidin nano-carriers suppresses cytokine-induced catabolism long term10.1016/j.joca.2015.07.010 ↗
55. Multi-arm Avidin nano-construct for intra-cartilage delivery of small molecule drugs10.1016/j.jconrel.2019.12.020 ↗
56. Poly-beta-amino-esters nano-vehicles based drug delivery system for cartilage10.1016/j.nano.2016.10.001 ↗
57. Synthetic nanoscale electrostatic particles as growth factor carriers for cartilage repair10.1002/btm2.10043 ↗
58. Engineering insulin-like growth factor-1 for local delivery10.1096/fj.07-100925 ↗
59. Intraarticular injection of heparin-binding insulin-like growth factor 1 sustains delivery of insulin-like growth factor 1 to cartilage through binding to chondroitin sulfate10.1002/art.27709 ↗
60. Targeted delivery to cartilage is critical for in vivo efficacy of insulin-like growth factor 1 in a rat model of osteoarthritis10.1002/art.38357 ↗
61. Optical imaging of mouse articular cartilage using the glycosaminoglycans binding property of fluorescent-labeled octaarginine10.1016/j.joca.2009.03.010 ↗
62. In vivo visualization of osteoarthritic hypertrophic lesions10.1039/C5SC01301A ↗
63. DOTAM derivatives as active cartilage-targeting drug carriers for the treatment of osteoarthritis10.1021/bc500557s ↗
64. Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display10.1016/j.biomaterials.2011.05.017 ↗
65. Identification of chondrocyte-binding peptides by phage display10.1002/jor.22325 ↗
66. Intra-articular delivery of anti-hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice10.1038/gt.2015.16 ↗
67. Chondrocyte affinity peptide modified PAMAM conjugate as a nanoplatform for targeting and retention in cartilage10.2217/nnm-2017-0335 ↗
68. Melittin derived peptides for nanoparticle based siRNA transfection10.1016/j.biomaterials.2013.01.037 ↗
69. Suppression of NF-κB activity via nanoparticle-based siRNA delivery alters early cartilage responses to injury10.1073/pnas.1608245113 ↗
70. Development of a peptide-siRNA nanocomplex targeting NF- κB for efficient cartilage delivery10.1038/s41598-018-37018-3 ↗
71. PEP-1-GRX-1 modulates matrix metalloproteinase-13 and nitric oxide expression of human articular chondrocytes10.1159/000456090 ↗
72. Interleukin-1 receptor antagonist (IL-1Ra) is more effective in suppressing cytokine-induced catabolism in cartilage-synovium co-culture than in cartilage monoculture10.1186/s13075-019-2003-y ↗
73. Sustained delivery of analgesic and antimicrobial agents to knee joint by direct injections of electrosprayed multipharmaceutical-loaded nano/microparticles10.3390/polym10080890 ↗
74. Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis10.1002/anie.201202713 ↗
75. Liposomal dexamethasone-diclofenac combinations for local osteoarthritis treatment10.1016/j.ijpharm.2009.04.025 ↗
76. Sustained intra-articular delivery of IL-1Ra from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis10.22203/eCM.v029a10 ↗
77. Chondroprotective effects of hyaluronic acid-chitosan nanoparticles containing plasmid DNA encoding cytokine response modifier a in a rat knee osteoarthritis model10.1159/000490217 ↗
78. Therapeutic potential of hyaluronic acid/chitosan nanoparticles for the delivery of curcuminoid in knee osteoarthritis and an in vitro evaluation in chondrocytes
79. Nanoparticles for improved local retention after intra-articular injection into the knee joint10.1007/s11095-012-0870-x ↗
80. Multi-scale imaging techniques to investigate solute transport across articular cartilage10.1016/j.jbiomech.2018.06.012 ↗
81. Nanoparticle properties for delivery to cartilage: the implications of disease state, synovial fluid, and off-target uptake10.1021/acs.molpharmaceut.7b00484 ↗
82. Electrostatic interactions enable rapid penetration, enhanced uptake and retention of intra-articular injected avidin in rat knee joints10.1002/jor.22630 ↗
83. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo10.1006/mthe.2000.0137 ↗
84. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium10.1016/S1525-0016(03)00181-3 ↗
85. Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis10.1016/j.clim.2014.01.005 ↗
86. Synovial fibroblast-targeting liposomes encapsulating an NF-κB-blocking peptide ameliorates zymosan-induced synovial inflammation10.1111/jcmm.13549 ↗
87. Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis10.1016/j.jconrel.2018.08.007 ↗
88. Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis10.1073/pnas.1103569108 ↗
89. Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide10.1136/annrheumdis-2012-201457 ↗
90. Metabolism of proteoglycans in tendon10.1111/j.1600-0838.2009.00938.x ↗
91. Tendon proteoglycans: biochemistry and function
92. Tendon injuries: basic science and new repair proposals10.1302/2058-5241.2.160075 ↗
93. Meniscal repair and regeneration: current strategies and future perspectives10.1016/j.jcot.2018.07.008 ↗
94. From repair to regeneration: biomaterials to reprogram the meniscus wound microenvironment10.1007/s10439-015-1249-z ↗
95. Suture techniques for tendon repair; A comparative review10.32098/mltj.03.2013.16 ↗
96. A suture technique for easier reduction and repair of bucket-handle meniscal tears while using the all-inside devices10.1051/sicotj/2016035 ↗
97. Clinical comparison of the autologous quadriceps tendon (BQT) and the autologous patella tendon (BPTB) for the reconstruction of the anterior cruciate ligament, knee surgery10.1007/s00167-007-0371-3 ↗
98. Meniscus allograft transplantation: a current concepts review, knee surgery10.1007/s00167-006-0216-5 ↗
99. Cell-based strategies for meniscus tissue engineering10.1155/2016/4717184 ↗
100. Tissue engineering strategies in ligament regeneration10.1155/2012/374676 ↗